RNA, U6 small nuclear 694, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-694P profile across patient tissues and cancer cell-line models. RNU6-694P expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RNU6-694P is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, RNU6-694P RNA expression shows 6,116 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, THCA, and STAD as cancer lineages where RNU6-694P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-694P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-694P survival associations across molecular data types. RNU6-694P RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-694P RNA expression–survival associations across cancer types. High RNU6-694P expression shows unfavorable associations in CHOL, KIRP, ACC, UCEC, DLBC and THCA. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for RNU6-694P RNA expression.
This table summarizes RNU6-694P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-694P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-694P shows lower tumor expression in THCA. The THCA box plot shows higher RNU6-694P RNA expression in normal versus tumor tissue (log2 FC = −0.185, t-test p = .002).
This table shows molecular features associated with RNU6-694P in patient tissues and cancer cell lines. In patient samples, RNU6-694P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
